OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a decline in revenue and increased losses, despite some growth in specific segments like the 4Kscore test. The Q&A section reveals uncertainties around key projects and a lack of detailed timelines for critical milestones. Although there's a commitment to shareholder returns through repurchases, the overall financial health and guidance adjustments suggest a negative sentiment, potentially leading to a stock price decrease.
Key Financial Performance
Diagnostics Revenue Q4 2025 $71.1 million, including $7 million from 4Kscore test, which grew by 16% compared to $6 million in Q4 2024. The year-over-year decline from $103.1 million in Q4 2024 was primarily due to the Labcorp transaction in September 2025 and test mix changes.
Diagnostics Operating Loss Q4 2025 $18.3 million, compared to $21.7 million in Q4 2024. The improvement was due to cost reduction initiatives and a streamlined geographic footprint.
Pharmaceutical Revenue Q4 2025 $77.4 million, compared to $80.5 million in Q4 2024. Product sales increased to $43.7 million from $37.4 million, driven by foreign exchange tailwinds and higher international sales volumes. Rayaldee contributed $8.8 million, slightly down from $9.1 million in Q4 2024 due to a 17% decline in volumes.
Pharmaceutical Operating Loss Q4 2025 $10.7 million, compared to $2.1 million in Q4 2024. The increase was due to higher R&D investments, particularly in ModeX development activities.
Consolidated Revenue Q4 2025 $148.5 million, compared to $183.6 million in Q4 2024. The decline was attributed to the Labcorp transaction and lower milestone payments from Merck compared to Regeneron.
Consolidated Operating Loss Q4 2025 $38.3 million, compared to $33.1 million in Q4 2024. The increase was due to reduced milestone payments and higher R&D investments.
Net Loss Q4 2025 $31.3 million, or $0.04 per share, compared to net income of $14 million, or $0.01 per diluted share, in Q4 2024. The decline was due to reduced milestone payments and gains from investments in the prior year.
4Kscore Test Volume Q4 2025 Increased by more than 6% year-over-year. The updated label, which no longer requires a digital rectal examination, supported this growth.
BARDA Funding 2025 $28.5 million, with a total of $54 million since inception. This funding supports COVID-19 and influenza antibody programs.
Share Repurchases 2025 $109 million in common shares and convertible notes repurchased, demonstrating a commitment to returning capital to shareholders.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ModeX pipeline: Multiple clinical-stage programs including an EBV vaccine partnered with Merck, immuno-oncology candidates, and immune rejuvenation therapies. Collaboration with Regeneron potentially exceeding $1 billion in milestones.
4Kscore test: National adoption with updated label, increased volume by 6% year-over-year, and entry into the primary care market.
OPK-88006: Advancing towards first-in-human phases for metabolic dysfunction-associated steatohepatitis (MASH).
Oral long-acting PTH tablet: Development in collaboration with Entera Bio for hypoparathyroidism, with IND application expected mid-2026.
BioReference transformation: Sale of oncology division to focus on core clinical laboratory business in New York and New Jersey, correctional health, and 4Kscore test nationally.
International pharmaceutical operations: 17% growth in global pharmaceutical product sales in 2025, with first royalty payment from Lilly for mazdutide in China.
Cost reduction initiatives: Workforce reduction by 29%, improved margins, and positive operating income expected for BioReference in 2026.
Capital allocation: Repurchased $109 million in common shares and convertible notes in 2025, with $113 million remaining for buybacks.
Regeneron collaboration: Aligning antibody discovery with multispecific platform for targets in metabolism, oncology, and immunology, with over $1 billion in potential milestones.
BARDA-supported programs: Received $28.5 million in 2025 for COVID-19 and influenza antibody programs, with clinical trials funded by BARDA.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Revenue from services is expected to be impacted by weather conditions in the Northeast, which have already caused a $3 million to $5 million reduction in volumes for January and February 2026.
Financial Performance: The company reported a net loss of $31.3 million for Q4 2025, compared to net income of $14 million in Q4 2024. This reflects challenges in maintaining profitability despite cost reduction efforts.
Operational Efficiency: The Diagnostics business experienced a decline in revenue due to the divestiture of oncology assets and a shift in test mix, which impacted profitability. Additionally, workforce reductions and asset write-offs were necessary to align with the new operating footprint.
Strategic Execution: The company faces risks in achieving its revenue and profitability targets for 2026, particularly in the Diagnostics and Pharmaceutical segments, as it transitions to a more focused business model.
Regulatory and Development Risks: The success of clinical trials and regulatory approvals for new products, such as MDX2301 and other pipeline candidates, is critical for future growth but remains uncertain.
Economic Uncertainties: Foreign exchange tailwinds contributed to revenue growth in international operations, but this factor is inherently volatile and could reverse.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For Q1 2026, total revenue is expected to be between $125 million and $140 million. For the full year 2026, total revenue is projected to be between $530 million and $560 million.
Pharmaceutical Product Revenue: Expected to be between $38 million and $45 million for Q1 2026, and $160 million to $170 million for the full year 2026.
Revenue from Services: Projected to be $71 million to $75 million for Q1 2026, and $300 million to $312 million for the full year 2026.
Other Revenue: Expected to be $15 million to $20 million for Q1 2026, and $70 million to $80 million for the full year 2026, including Pfizer's gross profit share of $34 million to $37 million.
Costs and Expenses: Total costs and expenses are expected to be between $170 million and $180 million for Q1 2026, and $725 million to $750 million for the full year 2026.
R&D Investments: R&D investments are expected to be $30 million to $32 million for Q1 2026, and $125 million to $135 million for the full year 2026, offset by $22 million to $26 million in BARDA funding and collaboration reimbursements.
Depreciation and Amortization: Expected to be approximately $24 million for Q1 2026, and $100 million for the full year 2026.
Share Repurchase Program: Approximately $113 million remains authorized for share repurchases, with plans to accelerate the program in the short term.
BioReference Diagnostics Business: Expected to deliver positive operating income and cash flow in 2026, supported by cost reduction initiatives and growth in 4Kscore test volumes.
ModeX Pipeline: Multiple clinical and partnership catalysts are anticipated in 2026, including the advancement of MDX2001, MDX2004, and MDX2003 programs.
BARDA-Supported Programs: MDX2301, a COVID multispecific antibody, is expected to enter the clinic in the first half of 2026. The influenza program is in the pre-IND stage, with potential incremental funding from BARDA.
In Vivo CAR-T Platform: Pre-IND process is in late stages, with plans to enter the clinic either late 2026 or early 2027.
OPK-88006 Development: Pre-IND work is in late stages, with plans to study metabolic dysfunction-associated steatohepatitis (MASH) participants and file an IND application mid-2026.
Oral Long-Acting PTH Tablet: Development is being accelerated, with plans to file an IND application mid-2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase Program: Last year, we bought back over $109 million in common shares and convertible notes. We have approximately $113 million remaining under our buyback authorization and expect to accelerate our repurchases over the short term. For the full year, we repurchased 34.6 million shares for approximately $47 million. We deployed over $109 million in convertible note and common stock repurchases during 2025 and almost $230 million since the start of 2024.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you discuss the timing of a potential data disclosure for MDX2001 and expectations for the proportion of evaluable patients?
A:The company has dosed 25 patients and sees signs of efficacy. They will announce Phase Ia trial results at an upcoming conference and enter Phase Ib for promising tumors. Results are expected by the end of 2026.
Q:Can you confirm whether you still plan to advance to the sixth dose level for MDX2001 or begin backfilling certain dose cohorts?
A:The company will not go to a much higher dose level based on current information. They are adjusting the regimen and focusing on the fifth dose level.
Q:What are the key drivers of the NGENLA profit share increase and assumptions for the guidance of $34 million to $37 million in 2026?
A:The increase is driven by global growth, regions moving up in tiering structure, and Pfizer gaining market share. The guidance is achievable at current growth rates and could accelerate with further global wins.
Q:Can you provide more color on the growth in the 4Kscore diagnostic test segment and its stability?
A:Growth is driven by the urology field, not primary care. Revenue growth came from improved revenue cycle management and payer mix. Growth is expected at a high-single-digit to low-double-digit pace into 2026, with potential acceleration as payers come along.
Q:What are the additional studies being performed for the Epstein-Barr virus vaccine to move into Phase II, and their timing?
A:Studies focus on EBV-naive patients and reducing the age of inclusion to 12 years. Data needed for decisions is expected by year-end, with Phase II starting next year.
Q:Has Merck made a go/no-go decision for the Epstein-Barr virus vaccine, and what is the current status?
A:The decision is for Merck to make. Data so far is encouraging, and the focus is on ensuring Phase II readiness. Final decisions will come from Merck.
Q:Can you reveal information on the GLP-1/glucagon combo assets and their current status?
A:The GLP-1/glucagon, or oxyntomodulin, is in late stages of IND submission. The oral formulation is promising, and the injectable is preparing for Phase I after IND clearance.
Q:Can you elaborate on the in vivo CAR-T technology and its delivery mechanism?
A:The technology uses lipid nanoparticles with mRNA or DNA cargo and covalently conjugated targeting antibodies. It targets T cells, B cells, and NK cells, enabling both monospecific and multispecific CAR-T development. Nonhuman primate experiments and CMC advancements are progressing.
Q:How do you envision developing MDX2004, the immune rejuvenator?
A:MDX2004 rejuvenates the immune system, particularly in cancer patients with exhausted immune systems. It is being tested in PD-1 naive and previously exposed patients. Eight patients have been dosed, and trials aim to determine tolerability and effectiveness.
Q:What are the specific clinical milestones for MDX2001 and MDX2004 in 2026?
A:For MDX2001, completion of dose regimen and entry into Phase Ib. For MDX2004, completion of Phase Ia to determine the optimal dose.
Q:Can you explain the BioReference margin expansion and the expense bridge, given the guidance of $725 million to $750 million in total expense?
A:Expense expansion is due to R&D efforts, while BioReference's operating efficiency and margin profile are improving. Operating company expenses are expected to remain stable or decline.
Q:Review of Unclear Management Responses
A:Management avoided directly answering whether Merck has made a final go/no-go decision for the Epstein-Barr virus vaccine, deferring the decision to Merck. Additionally, while discussing MDX2001 and MDX2004 milestones, the responses lacked detailed timelines and specifics beyond general goals.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Australia
BioReference oncology
CAR
CD cell
EBV vaccine
IND
PSA nodule
PTH
age PSA
antigen
application
asset sale
care
catalyst
class
collaboration Regeneron
dysfunction
entry
footprint
franchise
goal
immune
laboratory
metabolism oncology
mid
milestone
momentum
multispecific
nonhuman primate
oncology immunology
physician
platform
potential
program clinic
program development
rejuvenator cancer
royalty
target
tetraspecific antibody
tumor type
vaccine Merck
OPK Transcript
OPKO Health, Inc. (OPK) Q1 2026 Earnings Call Transcript
Unknown4-28
The earnings call summary reveals a decline in revenue and gross margin, alongside an increased net loss and operating expenses, which are negative indicators. The Q&A session did not provide additional insights or alleviate concerns. The lack of discussion on operational updates, strategic initiatives, and shareholder returns further contributes to uncertainty. Hence, the sentiment is negative, anticipating a stock price decline of -2% to -8% over the next two weeks.
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call highlights a decline in revenue and increased losses, despite some growth in specific segments like the 4Kscore test. The Q&A section reveals uncertainties around key projects and a lack of detailed timelines for critical milestones. Although there's a commitment to shareholder returns through repurchases, the overall financial health and guidance adjustments suggest a negative sentiment, potentially leading to a stock price decrease.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
Unknown10-29
The earnings call presents a mixed picture. Financial performance shows some decline in net income, but there's optimism in product development with potential growth in the 4Kscore product and new collaborations. Market strategy is unclear, with slow market conversion for Pfizer products. Expenses are high, impacting financial health. The shareholder return plan is not explicitly positive or negative. The Q&A reveals uncertainties in efficacy and market conversion. Overall, the rating is neutral due to balanced positives and negatives, with no strong catalysts for significant stock price movement.
OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
Positive7-31
The earnings call shows positive developments: a strategic sale to Labcorp, promising product development, and cost reduction initiatives. The Q&A highlights growth in NGENLA prescriptions, 4Kscore test sales, and potential for oxyntomodulin in obesity/MASH treatment. The share repurchase program and cash flow positive guidance further boost sentiment. Despite some management ambiguity, the overall outlook is positive, with optimistic guidance and strategic initiatives likely to drive a stock price increase in the short term.
OPK Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
